Current drug research on PEGylation with small molecular agents

Progress in Polymer Science

Volumn 38, Issue 3-4, 2013, Pages 421-444

  Li, Wenjun ^a   Zhan, Peng ^a   De Clercq, Erik ^b   Lou, Hongxiang ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Anti inflammatory; Anti tumor; Anti virus; Antimicrobial; Immunosuppressant; PEGylation; Small molecules drugs

Indexed keywords

FUNCTIONAL POLYMERS; MACROMOLECULES; MEDICAL APPLICATIONS; TUMORS; VIRUSES;

ANTI VIRUS; ANTI-INFLAMMATORIES; ANTI-TUMORS; ANTIMICROBIAL; IMMUNOSUPPRESSANT; PEGYLATION; SMALL MOLECULES;

DRUG DELIVERY;

EID: 84874391961     PISSN: 00796700     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.progpolymsci.2012.07.006     Document Type: Review

References (112)

1. G. Pasut, M. Sergi, and F.M. Veronese Anti-cancer PEG-enzymes: 30 years old, but still a current approach Advanced Drug Delivery Reviews 60 2008 69 78
2. S. Brocchini, A. Godwin, S. Balan, J. Choi, M. Zloh, and S. Shaunak Disulfide bridge based PEGylation of proteins Advanced Drug Delivery Reviews 60 2008 3 12
3. Y. Eto, Y. Yoshioka, Y. Mukai, N. Okada, and S. Nakagawa Development of PEGylated adenovirus vector with targeting ligand International Journal of Pharmaceutics 354 2008 3 8
4. L. Huynh, C. Neale, R. Pomès, and C. Allen Computational approaches to the rational design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery Nanomedicine 8 2012 20 36
5. R.W. Payne, B.M. Murphy, and M.C. Manning Product development issues for PEGylated proteins Pharmaceutical Development and Technology 16 2011 423 440
6. A. Abuchowski, T. Van Es, N.C. Palczuk, and F.F. Davis Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol Journal of Biological Chemistry 252 1977 3578 3581
7. A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, and F.F. Davis Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase Journal of Biological Chemistry 252 1977 3582 3586
8. C. Li, and S. Wallace Polymer-drug conjugates: recent development in clinical oncology Advanced Drug Delivery Reviews 60 2008 886 898
9. G. Pasut, and F.M. Veronese Polymer-drug conjugation, recent achievements and general strategies Progress in Polymer Science 32 2007 933 961
10. N. Li, D. Ziegemeier, L. Bass, and W. Wang Quantitation of free polyethylene glycol in PEGylated protein conjugate by size exclusion HPLC with refractive index (RI) detection Journal of Pharmaceutical and Biomedical Analysis 48 2008 1332 1338
11. Y.S. Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens, and D.F. Wyss Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Advanced Drug Delivery Reviews 54 2002 547 570
12. J.S. Kang, P.P. DeLuca, and K.C. Lee Emerging PEGylated drugs Expert Opinion on Emerging Drugs 14 2009 363 380
13. R. Duncan Polymer therapeutics as nanomedicines: new perspectives Current Opinion in Biotechnology 22 2011 492 501
14. C. Chen, A. Constantinou, and M. Deonarain Modulating antibody pharmacokinetics using hydrophilic polymers Expert Opinion on Drug Delivery 8 2011 1221 1236
15. R. Gaspar, and R. Duncan Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics Advanced Drug Delivery Reviews 61 2009 1220 1231
16. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discovery Today 10 2005 1451 1458
17. M.J. Vicent, H. Ringsdorf, and R. Duncan Polymer therapeutics: clinical applications and challenges for development Advanced Drug Delivery Reviews 61 2009 1117 1120
18. Bentley MD, Roberts MJ, Shen X, Cheng L. Polymer conjugates of opioid antagonists. US7662365 B2; 2010.
19. Kozlowski A, McManus SP, Riggs-Sauthier J, Shen X, Zhang W. Multi-arm polymeric alkanoate conjugates. US 2011/0200550 A1; 2011.
20. L. Kelland Discontinued drugs in 2005: oncology drugs Expert Opinion on Investigational Drugs 15 2006 1309 1318
21. K. Hoste, K. De Winne, and E. Schacht Polymeric prodrugs International Journal of Pharmaceutics 277 2004 119 131
22. D. Filpula, and H. Zhao Releasable PEGylation of proteins with customized linkers Advanced Drug Delivery Reviews 60 2008 29 49
23. R.B. Greenwald, Y.H. Choe, J. McGuire, and C.D. Conover Effective drug delivery by PEGylated drug conjugates Advanced Drug Delivery Reviews 55 2003 217 250
24. T. Minko Soluble polymer conjugates for drug delivery Drug Discovery Today: Technologies 2 2005 15 20
25. W. Li, Y. Chang, P. Zhan, N. Zhang, X. Liu, C. Pannecouque, and E. De Clercq Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3′-azido-3′- deoxythymidine (AZT, zidovudine) ChemMedChem 5 2010 1893 1898
26. M. Hamidi, P. Rafiei, and A. Azadi Designing PEGylated therapeutic molecules: advantages in ADMET properties Expert Opinion on Drug Delivery 3 2008 1293 1307
27. C.J. Fee, and J.M. Van Alstine PEG-proteins: reaction engineering and separation issues Chemical Engineering Science 61 2005 924 939
28. H. Ringsdorf Structure and properties of pharmacologically active polymers Journal of Polymer Science: Polymer Symposia 51 1975 135 153
29. P. Caliceti, and F.M. Veronese Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates Advanced Drug Delivery Reviews 55 2003 1261 1277
30. J. Khandare, and T. Minko Polymer-drug conjugates: progress in polymeric prodrugs Progress in Polymer Science 31 2006 359 397
31. P. Kolhe, J. Khandare, O. Pillai, S. Kannan, M. Lieh-Lai, and R. Kannan Hyperbranched polymer-drug conjugates with high drug payload for enhanced cellular delivery Pharmaceutical Research 21 2004 2185 2195
32. H. Zhao, L.M. Greenberger, and I.D. Horak Drug conjugates with poly (ethylene glycol) F. Kratz, P. Senter, H. Steinhager, Drug delivery in oncology: from basic research to cancer therapy vol. 2 2012 Wiley-VCH Weinheim 627 666
33. R. Mahato, W. Tai, and K. Cheng Prodrugs for improving tumor targetability and efficiency Advanced Drug Delivery Reviews 63 2011 659 670
34. E. Markovsky, H. Baabur-Cohen, A. Eldar-Boock, L. Omer, G. Tiram, S. Ferber, P. Ofek, D. Polyak, A. Scomparin, and R. Satchi-Fainaro Administration, distribution, metabolism and elimination of polymer therapeutics Journal of Controlled Release 61 2012 446 460
35. C.J. Langer CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes Clinical Lung Cancer 6 Suppl. 2004 85 88
36. F. Greco, and M.J. Vicent Polymer-drug conjugates: current status and future trends Frontiers in Bioscience 13 2008 2256 2744
37. A.S. Hoffman, and P.S. Stayton Conjugates of stimuli-responsive polymers and proteins Progress in Polymer Science 32 2007 922 932
38. S. Jayant, J.J. Khandare, Y. Wang, A.P. Singh, N. Vorsa, and T. Minko Targeted sialic acid-Doxorubicin prodrugs for intracellular delivery and cancer treatment Pharmaceutical Research 24 2007 2120 2130
39. T. Murakami, J. Fan, M. Yudasaka, S. Iijima, and K. Shiba Solubilization of single-wall carbon nanohorns using a PEG-doxorubicin conjugate Molecular Pharmaceutics 3 2006 407 414
40. F.M. Veronese, O. Schiavon, G. Pasut, R. Mendichi, L. Andersson, A. Tsirk, J. Ford, G. Wu, S. Kneller, J. Davies, and R. Duncan PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity Bioconjugate Chemistry 16 2005 775 784
41. N. Cao, and S.S. Feng Doxorubicin conjugated to d-[α]-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation Biomaterials 29 2008 3856 3865
42. V. Anbharasi, N. Cao, and S.S. Feng Doxorubicin conjugated to d-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy Journal of Biomedical Materials Research A 94 2010 730 743
43. S. Zhu, L. Qian, M. Hong, L. Zhang, Y. Pei, and Y. Jiang RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor Advanced Materials 23 2011 H84 H89
44. S. Zhu, M. Hong, L. Zhang, G. Tang, Y. Jiang, and Y. Pei PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation Pharmaceutical Research 27 2010 161 174
45. L. Zhang, S. Zhu, L. Qian, Y. Pei, Y. Qiu, and Y. Jiang RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma European Journal of Pharmaceutics and Biopharmaceutics 79 2011 232 240
46. U. Hoch, L. Masuoka, D. Maslyar, and D. Von Hoff NKTR-102 demonstrates nonclinical and phase I clinical anti-tumor activity in ovarian cancer European Journal of Cancer. Supplements 7 2 2009 454
47. Zhao X, Bentley MD, Ren Z, Viegas TX. Multi-arm polymer prodrugs. US 2009/0074704 A1; 2009.
48. Zhang W. Method for preparing a polymer conjugate. US 2010/0010194 A1; 2010.
49. Santi DV, Ashley GW, Hearn B. Prodrugs and drug-macromolecule conjugates having controlled drug release rates. US 2011/0263502 A1; 2011.
50. Eldon MA, Harite SS, Barker TL. Compositions and methods for achieving sustained therapeutic drug concentrations in a subject. US 2011/0269789 A1; 2011.
51. R.P. Hertzberg, M.J. Caranfa, and S.M. Hecht On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex Biochemistry 28 1989 4629 4638
52. P. Opanasopit, T. Ngawhirunpat, A. Chaidedgumjorn, T. Rojanarata, A. Apirakaramwong, S. Phongying, C. Choochottiros, and S. Chirachanchai Incorporation of camptothecin into N-phthaloyl chitosan-g-mPEG self-assembly micellar system European Journal of Pharmaceutics and Biopharmaceutics 64 2006 269 276
53. A. Guiotto, M. Canevari, P. Orsolini, O. Lavanchy, C. Deuschel, N. Kaneda, A. Kurita, T. Matsuzaki, T. Yaegashi, S. Sawada, and F.M. Veronese Efficient and chemoselective N-acylation of 10-amino-7-ethyl camptothecin with poly (ethylene glycol) Bioorganic and Medicinal Chemistry Letters 14 2004 1803 1805
54. A.B. Fleming, K. Haverstick, and W.M. Saltzman In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain Bioconjugate Chemistry 15 2004 1364 1375
55. J.A. Posey 3rd, M.W. Saif, R. Carlisle, A. Goetz, J. Rizzo, S. Stevenson, M.S. Rudoltz, J. Kwiatek, P. Simmons, E.K. Rowinsky, C.H. Takimoto, and A.W. Tolcher Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas Clinical Cancer Research 11 2005 7866 7871
56. L.C. Scott, J.C. Yao, A.B. Benson 3rd, A.L. Thomas, S. Falk, R.R. Mena, J. Picus, J. Wright, M.F. Mulcahy, J.A. Ajani, and T.R. Evans A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma Cancer Chemotherapy and Pharmacology 63 2009 363 370
57. G. Pasut, and F.M. Veronese PEG conjugates in clinical development or use as anticancer agents: an overview Advanced Drug Delivery Reviews 61 2009 1177 1188
58. H. Zhao, B. Rubio, P. Sapra, D. Wu, P. Reddy, P. Sai, A. Martinez, Y. Gao, Y. Lozanguiez, C. Longley, L.M. Greenberger, and I.D. Horak Novel prodrugs of SN38 using multiarm poly (ethylene glycol) linkers Bioconjugate Chemistry 19 2008 849 859
59. P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L.M. Greenberger, and I.D. Horak Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model Clinical Cancer Research 14 2008 1888 1896
60. Y. Matsumura Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect Advanced Drug Delivery Reviews 63 2011 184 192
61. P. Sapra, P. Kraft, F. Pastorino, D. Ribatti, M. Dumble, M. Mehlig, M. Wang, M. Ponzoni, L.M. Greenberger, and I.D. Horak Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate EZN-2208, results in anti-angiogenic effects Angiogenesis 14 2011 245 253
62. F. Pastorino, M. Loi, P. Sapra, P. Becherini, M. Cilli, L. Emionite, D. Ribatti, L.M. Greenberger, I.D. Horak, and M. Ponzoni Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor Clinical Cancer Research 16 2010 4809 4821
63. G. Qu, Z. Yao, C. Zhang, X. Wu, and Q. Ping PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation European Journal of Pharmaceutical Sciences 37 2009 98 105
64. R.B. Greenwald, C.W. Gilbert, A. Pendri, C.D. Conover, J. Xia, and A. Martinez Drug delivery systems: water soluble taxol 2′-poly (ethylene glycol) ester prodrugs design and in vivo effectiveness Journal of Medicinal Chemistry 39 1996 424 431
65. M. Beeram, E.K. Rowinsky, L.A. Hammond, A. Patnaik, G.H. Schwartz, J.S. de Bono, L. Forero, B. Forouzesh, E.H. Rubin, S. Beers, L. Spivey, A. Killian, J. Kwiatek, J. McGuire, and C.H. Takimoto A phase I and pharmacokinetic (PK) study of PEG-Paclitaxel in patients with advanced solid tumors Proceedings of American Society of Clinical Oncology 21 2002 abstr 405
66. X. Zhang, Y. Li, X. Chen, X. Wang, X. Xu, Q. Liang, J. Hu, and X. Jing Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate Biomaterials 26 2005 2121 2128
67. Z.G. Xie, T.C. Lu, X.S. Chen, C.H. Lu, Y.H. Zheng, and X.B. Jing Triblock poly(lactic acid)-b-poly(ethylene glycol)-b-poly(lactic acid)/Paclitaxel conjugates: synthesis, micellization, and cytotoxicity Journal of Applied Polymer Science 105 2007 2271 2279
68. Z. Xie, H. Guan, X. Chen, C. Lu, L. Chen, X. Hu, Q. Shi, and X. Jing A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer Journal of Controlled Release 117 2007 210 216
69. Z. Xie, T. Lu, X. Chen, Y. Zheng, and X. Jing Synthesis, self-assembly in water, and cytotoxicity of mPEG-block-PLLA/DX conjugates Journal of Biomedical Materials Research A 88 2009 238 245
70. Harada M, Saito H, Kato Y. Polymer derivative of docetaxel, method of preparing the same and uses thereof. US 2011/0136990 A1; 2011.
71. E. Calvo, U. Hoch, D.J. Maslyar, and A.W. Tolcher Dose-escalation phase I study of NKTR-105, a novel pegylated form of docetaxel Journal of Clinical Oncology 28 15 Suppl. 2010 abstr TPS160
72. Eliasof S, Crawford TC, Gangal G, Reiter LA, Ng P. Polymer-agent conjugates, particles, compositions, and related methods of use. US 2011/0189092 A1; 2011.
73. X. Li, R. Li, X. Qian, Y. Ding, Y. Tu, R. Guo, Y. Hu, X. Jiang, W. Guo, and B. Liu Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate European Journal of Pharmaceutics and Biopharmaceutics 70 2008 726 734
74. P. Nygren, and B. Glimelius The Swedish council on technology assessment in health care (SBU) report on cancer chemotherapy-project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation Acta Oncologica 40 2001 155 165
75. S.A. Hundahl Surgical quality in trials of adjuvant cancer therapy Journal of Surgical Oncology 80 2002 177 180
76. E.C. Gryparis, M. Hatziapostolou, E. Papadimitriou, and K. Avgoustakis Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells European Journal of Pharmaceutics and Biopharmaceutics 67 2007 1 8
77. O. Aronov, A.T. Horowitz, A. Gabizon, and D. Gibson Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies Bioconjugate Chemistry 14 2003 563 574
78. T. Hoang, K.M. Kim, A. Jaslowski, P. Koch, P. Beatty, J. McGovern, M. Quisumbing, G. Shapiro, R. Witte, and J.H. Schiller Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Lung Cancer 42 2003 97 102
79. G. Pasut, F. Canal, L. Dalla Via, S. Arpicco, F.M. Veronese, and O. Schiavon Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid Journal of Controlled Release 127 2008 239 248
80. R.M. Schultz, R.L. Merriman, S.L. Andis, R. Bonjouklian, G.B. Grindey, P.G. Rutherford, A. Gallegos, K. Massey, and G. Powis In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin Anticancer Research 15 1995 1135 1139
81. B.H. Norman, C. Shih, J.E. Toth, J.E. Ray, J.A. Dodge, D.W. Johnson, P.G. Rutherford, R.M. Schultz, J.F. Worzalla, and C.J. Vlahos Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs Journal of Medicinal Chemistry 39 1996 1106 1111
82. T. Zhu, J. Gu, K. Yu, J. Lucas, P. Cai, R. Tsao, Y. Gong, F. Li, I. Chaudhary, P. Desai, M. Ruppen, M. Fawzi, J. Gibbons, S. Ayral-Kaloustian, J. Skotnicki, T. Mansour, and A. Zask Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models Journal of Medicinal Chemistry 49 2006 1373 1378
83. A. Rossi, S. Ricciardi, P. Maione, F. de Marinis, and C. Gridelli Pemetrexed in the treatment of advanced non-squamous lung cancer Lung Cancer 66 2009 141 149
84. T. Min, H. Ye, P. Zhang, J. Liu, C. Zhang, W.B. Shen, W. Wang, and L.S. Shen Water-soluble poly(ethylene glycol) prodrug of pemetrexed: synthesis, characterization, and preliminary cytotoxicity Journal of Applied Polymer Science 111 2009 444 451
85. D. Pla, A. Francesch, P. Calvo, C. Cuevas, R. Aligué, F. Albericio, and M. Alvarez Lamellarin D bioconjugates I: synthesis and cellular internalization of PEG-derivatives Bioconjugate Chemistry 20 2009 1100 1111
86. D. Pla, M. Martí, J. Farrera-Sinfreu, D. Pulido, A. Francesch, P. Calvo, C. Cuevas, M. Royo, R. Aligué, F. Albericio, and M. Alvarez Lamellarin D bioconjugates II: synthesis and cellular internalization of dendrimer and nuclear location signal derivatives Bioconjugate Chemistry 20 2009 1112 1121
87. N. Kohler, C. Sun, J. Wang, and M. Zhang Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells Langmuir 21 2005 8858 8864
88. K. Riebeseel, E. Biedermann, R. Löser, N. Breiter, R. Hanselmann, R. Muelhaupt, C. Unger, and F. Kratz Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40,000; synthesis, characterization, and structure-activity relationships in vitro and in vivo Bioconjugate Chemistry 13 2002 773 785
89. G. Qu, X. Zhu, C. Zhang, and Q. Ping Modified chitosan derivative micelle system for natural anti-tumor product gambogic acid delivery Drug Delivery 16 2009 363 370
90. X. Tang, P. Zhang, H. Ye, C. Zhang, W. Shen, and Q. Ping Water-soluble gambogic acid PEGylated prodrugs: synthesis, characterization, physicochemical properties and in vitro hydrolysis Pharmazie 63 2008 711 717
91. C.M. Buchanan, N.L. Buchanan, K.J. Edgar, J.L. Little, M.G. Ramsey, K.M. Ruble, V.J. Wacher, and M.F. Wempe Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-β-cyclodextrin formulations Biomacromolecules 9 2008 305 313
92. S. Gunaseelan, O. Debrah, L. Wan, M.J. Leibowitz, A.B. Rabson, S. Stein, and P.J. Sinko Synthesis of poly (ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay Bioconjugate Chemistry 15 2004 1322 1333
93. M. Fresta, G. Fontana, C. Bucolo, G. Cavallaro, G. Giammona, and G. Puglisi Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir Journal of Pharmaceutical Sciences 90 2001 288 297
94. M. Zacchigna, G. Di Luca, V. Maurich, and Boccù E Syntheses, chemical and enzymatic stability of new poly (ethylene glycol)-acyclovir prodrugs Il Farmaco 57 2002 207 214
95. W.J. Li, J.D. Wu, P. Zhan, Y. Chang, C. Pannecouque, E. De Clercq, and X.Y. Liu Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates International Journal of Biological Macromolecules 50 2012 974 980
96. E.J. Ruijgrok, A.G. Vulto, and E.W.M. van Etten Sterically stabilized liposomes containing gentamicin: limitations to gentamicin encapsulation Journal of Liposome Research 9 1999 291 300
97. Y. Marcus, K. Sasson, M. Fridkin, and Y. Shechter Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin Journal of Medicinal Chemistry 51 2008 4300 4305
98. B.E. Cohen Amphotericin B toxicity and lethality: a tale of two channels International Journal of Pharmaceutics 162 1998 95 106
99. M. Sedlák, V. Buchta, L. Kubicová, P. Simůnek, M. Holcapek, and P. Kasparová Synthesis and characterisation of a new amphotericin B-methoxypoly (ethylene glycol) conjugate Bioorganic and Medicinal Chemistry Letters 11 2001 2833 2835
100. M. Sedlák, M. Pravda, F. Staud, L. Kubicová, K. Týcová, and K. Ventura Synthesis of pH-sensitive amphotericin B-poly (ethylene glycol) conjugates and study of their controlled release in vitro Bioorganic and Medicinal Chemistry 15 2007 4069 4076
101. K. Reimer, M. Hopp, M. Zenz, C. Maier, P. Holzer, G. Mikus, B. Bosse, K. Smith, C. Buschmann-Kramm, and P. Leyendecker Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach Pharmacology 83 2009 10 17
102. W.R. Hipkin, and R.E. Dolle Chapter 9-opioid receptor antagonists for gastrointestinal dysfunction J.C. Barrish, D. Weinstein, Annu Rep Med Chem Part III: inflammation/pulmonary/gastrointestinal diseases vol. 45 2010 Bristol-Myers Squibb R&D Princeton, NJ 142 155
103. L. Webster, E.R. Blonsky, P. Matz, D. Levinsky, R. Martz, S. Dhar, T. Neumann, M. Eldon, and T. Patrick Efficacy, safety and pharmacokinetics of oral NKTR-118 in patients with opioid-induced constipation: results of a randomized, double-blind. Placebo-controlled phase 2 study American Journal of Gastroenterology 104 2009 S174
104. Fishburn CS, Lechuga-Ballesteros D, Viegas T, Kuo M, Song Y, Gursahani H, Leach C. Chemically modified small molecules. US 2010/0210676 A1; 2010.
105. S. Gale, and G. Croasdell 28th annual JPMorgan healthcare conference - exelixis and nektar therapeutics IDrugs 13 2010 139 141
106. C.S. Fishburn The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics Journal of Pharmaceutical Sciences 97 2008 4167 4183
107. K. Yamashita, T. Nakate, K. Okimoto, A. Ohike, Y. Tokunaga, R. Ibuki, K. Higaki, and T. Kimura Establishment of new preparation method for solid dispersion formulation of tacrolimus International Journal of Pharmaceutics 267 2003 79 91
108. Y. Chung, and H. Cho Preparation of highly water soluble tacrolimus derivatives: poly (ethylene glycol) esters as potential prodrugs Archives of Pharmacal Research 27 2004 878 883
109. X. Yanyu, S. Yunmei, C. Zhipeng, and P. Qineng The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats International Journal of Pharmaceutics 307 2006 77 82
110. P. Zhang, H. Ye, T. Min, and C. Zhang Water soluble poly (ethylene glycol) prodrug of silybin: design, synthesis, and characterization Journal of Applied Polymer Science 107 2008 3230 3235
111. J. Li, Y. Wang, C. Yang, P. Wang, D.K. Oelschlager, Y. Zheng, D.A. Tian, W.E. Grizzle, D.J. Buchsbaum, and M. Wan Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1 Molecular Pharmacology 76 2009 81 90
112. P. Bailon, and C.Y. Won PEG-modified biopharmaceuticals Expert Opinion on Drug Delivery 6 2009 1 16